IMGT/mAb-DB card

Version: 2.0.4 (2023-04-14)

Citing IMGT/mAb-DB

Manso T., Kushwaha A., Abdollahi N., Duroux P., Giudicelli V. and Kossida S. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol., 14 (2023). DOI 10.3389/fimmu.2023.1129323

Poiron C., Wu Y., Ginestoux C., Ehrenmann, Duroux P. and Lefranc M.-P. IMGT/mAb-DB: the IMGT® database for therapeutic monoclonal antibodies. JOBIM 2010, Paper 13 (2010). Abstract

Cambon M., Cherouali K., Kushwaha A., Giudicelli V., Duroux P., Kossida S. and Lefranc M.-P. IMGT/mAb-DB and IMGT/2Dstructure-DB for IMGT standard definition of an antibody: from receptor to amino acid changes. JOBIM 2018, Poster 201 (2018). Abstract

IMGT/mAb-DB ID	1106
INN	cilgavimab
INN Number	11777
INN Prop. List	124 (2020)
INN Rec. List	85 (2021)
Common name	AZD1061, COV2-2130, 2130, AZD7442
Proprietary name	EVUSHELD™ (combination of cilgavimab and tixagevimab)
Species	Homo sapiens
IMGT receptor type	IG
Format (legend)
Receptor identification	IgG1 - kappa
Radiolabelled / Conjugated / Fused
IMGT/2Dstructure-DB	11777
IMGT/3Dstructure-DB
Specificity target name and species	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike (S) glycoprotein receptor binding domain (RBD) [Homo sapiens]
Development Technology
Origin clone species
Origin clone name

Company	AstraZeneca (London UK)
Expression system	CHO (Chinese Hamster Ovary) cells
Application	Therapeutic
Clinical domain	Infectiology
Mechanism of action
Clinical indication	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19)
Development status	Phase I
Regulatory agency status and year	FDA approval August 12, 2021

Clinical trials
Authority decisions
External links
IMGT notes	WHO Drug Information, Vol. 34, No. 3, 2020. Proposed INN List 124 – COVID-19 (special edition) (9 October 2020) pages 642-669. Proposed INN List 124 (19 December 2020, published on 22 January 2021) pages 929-1102. On August 12, 2021, Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of tixagevimab with cilgavimab as pre-exposure prophylaxis for prevention of coronavirus disease 2019 (COVID-19) in adults and pediatric individuals. Press release. Letter of authorization.
Biosimilars

Format legend:

IMGT/mAb-DB query | IMGT/mAb-DB documentation